• Vir Biotechnology Inc VIR.OQ reported a quarterly adjusted loss of $1.56​​ per share for the quarter ended January 1, lower than the same quarter last year, when the company reported EPS of $-1.22. The mean expectation of eight analysts for the quarter was for a loss of $1.05 per share. Wall Street expected results to range from $-1.75 to -85 cents per share.

• Revenue fell 9.8% to $2.38 million from a year ago; analysts expected $5.51 million.

• Vir Biotechnology Inc's reported EPS for the quarter was a loss of $1.56​.

• The company reported a quarterly loss of $213.72 million.

• Vir Biotechnology Inc shares had risen by 1.5% this quarter and lost 24.5% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 1.2% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Vir Biotechnology Inc is $21.00

This summary was machine generated from LSEG data November 1 at 03:33 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)